Form 4: Elanco Animal Health Director R. David Hoover Reports Stock Transactions

R. David Hoover, a director at Elanco Animal Health, reported the acquisition of 18,169 shares of common stock and the disposal of 185,000 shares held in a revocable trust.

Summary

• R. David Hoover, a director at Elanco Animal Health, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• The filing reports the acquisition of 18,169 shares of common stock, granted as deferred stock units as part of an annual equity award to non-employee board members.
• It also reports the disposal of 185,000 shares of common stock held indirectly through a revocable trust.
• Following these transactions, Mr. Hoover directly owns 96,459 shares and indirectly owns 15,920 shares through the Suzanne A. Hoover Revocable Trust.

Sentiment

Score: 5

Explanation: The document is a routine filing of insider transactions. The acquisition of shares is a positive sign, while the disposal of shares from a trust is neutral. Overall, the sentiment is neutral.

Positives

• The acquisition of 18,169 shares indicates continued alignment of interests between the director and the company's performance.

Negatives

• The disposal of 185,000 shares, while held in a revocable trust, could be perceived negatively by some investors.

Risks

• Significant stock disposals by insiders can sometimes signal a lack of confidence in the company's future performance, although this is not necessarily the case here as the shares were held in a revocable trust.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the animal health industry and all publicly traded companies. It provides transparency into the ownership changes of key personnel.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, including Elanco's competitors such as Zoetis and Merck Animal Health.
• The reporting of stock transactions by directors is a common occurrence and is generally in line with industry standards for corporate governance and transparency.

Stakeholder Impact

• The stock transactions may have a minor impact on shareholder sentiment, but are unlikely to significantly affect the company's operations or other stakeholders.

Key Dates

Keywords

Elanco Animal Health, Form 4, Beneficial Ownership, Stock Transactions, Director, R. David Hoover, Equity Award, Deferred Stock Units, Revocable Trust